NASDAQ:ATRS - Antares Pharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.18 0.00 (0.00 %)
(As of 12/10/2018 04:00 PM ET)
Previous Close$3.18
Today's Range$3.09 - $3.19
52-Week Range$1.75 - $3.93
Volume934,689 shs
Average Volume1.26 million shs
Market Capitalization$500.98 million
P/E Ratio-28.91
Dividend YieldN/A
Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector II needle-free auto injectors to administer human growth hormone for patients with growth retardation; and VIBEX disposable pressure-assisted auto injectors. In addition, the company develops XYOSTED for the treatment of testosterone deficiency in adult males; VIBEX auto injectors for treating anaphylaxis; and disposable pen injectors for diabetes and osteoporosis. It has strategic alliances with Teva Pharmaceutical Industries, Ltd. and AMAG Pharmaceuticals, Inc., as well as a development agreement with Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
Current SymbolNASDAQ:ATRS
Previous Symbol


Debt-to-Equity Ratio1.03
Current Ratio2.29
Quick Ratio1.83


Trailing P/E Ratio-28.91
Forward P/E Ratio-31.80
P/E GrowthN/A

Sales & Book Value

Annual Sales$54.51 million
Price / Sales9.19
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.21 per share
Price / Book15.14


EPS (Most Recent Fiscal Year)($0.11)
Net Income$-16,740,000.00
Net Margins-27.84%
Return on Equity-59.08%
Return on Assets-22.25%


Outstanding Shares157,540,000
Market Cap$500.98 million

Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

How were Antares Pharma's earnings last quarter?

Antares Pharma Inc (NASDAQ:ATRS) posted its quarterly earnings results on Tuesday, November, 6th. The specialty pharmaceutical company reported ($0.01) earnings per share for the quarter, beating analysts' consensus estimates of ($0.02) by $0.01. The specialty pharmaceutical company had revenue of $17.87 million for the quarter, compared to the consensus estimate of $15.13 million. Antares Pharma had a negative net margin of 27.84% and a negative return on equity of 59.08%. View Antares Pharma's Earnings History.

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, March 12th 2019. View Earnings Estimates for Antares Pharma.

What price target have analysts set for ATRS?

4 brokers have issued 12-month price targets for Antares Pharma's stock. Their predictions range from $4.00 to $8.00. On average, they expect Antares Pharma's share price to reach $5.4375 in the next year. This suggests a possible upside of 71.0% from the stock's current price. View Analyst Price Targets for Antares Pharma.

What is the consensus analysts' recommendation for Antares Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Antares Pharma.

Has Antares Pharma been receiving favorable news coverage?

News coverage about ATRS stock has trended very positive on Monday, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Antares Pharma earned a daily sentiment score of 3.9 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future.

Who are some of Antares Pharma's key competitors?

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the folowing people:
  • Mr. Robert F. Apple, CEO, Pres & Director (Age 52)
  • Mr. Fred M. Powell, Exec. VP & CFO (Age 57)
  • Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 51)
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. and Corp. Controller (Age 55)
  • Edward Kessig, VP of Sales

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.31%), Vanguard Group Inc. (4.12%), FMR LLC (2.27%), Mycio Wealth Partners LLC (1.37%), JW Asset Management LLC (1.22%) and Russell Investments Group Ltd. (0.71%). Company insiders that own Antares Pharma stock include Fred M Powell, Jacques Gonella, Leonard S Jacob, Robert F Apple and Thomas J Garrity. View Institutional Ownership Trends for Antares Pharma.

Which major investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Mycio Wealth Partners LLC, FMR LLC, Russell Investments Group Ltd., AQR Capital Management LLC, Bank of New York Mellon Corp and Falcon Point Capital LLC. Company insiders that have sold Antares Pharma company stock in the last year include Jacques Gonella and Robert F Apple. View Insider Buying and Selling for Antares Pharma.

Which major investors are buying Antares Pharma stock?

ATRS stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., JPMorgan Chase & Co., Allianz Asset Management GmbH, BlackRock Inc., Perkins Capital Management Inc., Morgan Stanley, JW Asset Management LLC and Vanguard Group Inc.. View Insider Buying and Selling for Antares Pharma.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $3.18.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $500.98 million and generates $54.51 million in revenue each year. The specialty pharmaceutical company earns $-16,740,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Antares Pharma employs 111 workers across the globe.

What is Antares Pharma's official website?

The official website for Antares Pharma is

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]

MarketBeat Community Rating for Antares Pharma (NASDAQ ATRS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  207 (Vote Underperform)
Total Votes:  494
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by Staff

Featured Article: Bond

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel